Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Exelixis (EXEL)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elevance Health (ELV – Research Report) and Exelixis (EXEL – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Elevance Health (ELV)
RBC Capital analyst Ben Hendrix maintained a Buy rating on Elevance Health yesterday and set a price target of $392.00. The company’s shares closed last Thursday at $372.24, close to its 52-week low of $362.21.
According to TipRanks.com, Hendrix is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Elevance Health with a $396.17 average price target, which is a 7.5% upside from current levels. In a report issued on January 7, Wolfe Research also upgraded the stock to Buy with a $425.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Exelixis (EXEL)
In a report issued on January 21, Leonid Timashev from RBC Capital maintained a Hold rating on Exelixis, with a price target of $45.00. The company’s shares closed last Thursday at $44.50.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of
Currently, the analyst consensus on Exelixis is a Moderate Buy with an average price target of $45.80, representing a 1.8% upside. In a report issued on January 12, Stifel Nicolaus also reiterated a Hold rating on the stock with a $43.00 price target.
